Shengqing Gu - Concepedia

Concepedia

Author

Shengqing Gu

Dana-Farber Cancer Institute ORCID

Also Known As

Gu, Shengqing, Gu, Shengqing Stan, Hendrickx, Wouter R. L., S Gu, S. Gu, Sheng-Qing Gu, Shengqing (Stan) Gu, Shengqing Gu, Shengqing S. Gu, Shengqing Stan Gu

234

Publications

7.8K

Citations

26

H-Index

66

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University Tongji University University of Toronto Broad Institute

SG

About

Shengqing Gu is an author at Dana-Farber Cancer Institute specializing in medicine, immunology, and tumor immunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	6K
2	Natural Sciences	2	2	238
3	Engineering	1	1	38
4	Health Sciences	1	1	19
5	Allergy	1	1	20

Shengqing Gu

×

39

Publications

7.8K

Citations

26

H-Index

	Year	Citations
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response Peng Jiang, Shengqing Gu, Deng Pan, Nature Medicine Cancer ImmunosurveillanceT Cell DysfunctionT-regulatory CellImmunologyTumor Immunity	2018	5.4K
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade Shengqing Gu, Wubing Zhang, Xiaoqing Wang, Cancer Discovery	2021	267
Landscape of B cell immunity and related immune evasion in human cancers Xihao Hu, Jian Zhang, Jin Wang, Nature Genetics Cancer ImmunosurveillanceB Cell ImmunityImmunologyTumor ImmunityImmunoediting	2019	213
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer Changxin Wan, Matthew P. Keany, Han Dong, Cancer Research	2020	204
Loss of Tankyrase-Mediated Destruction of 3BP2 Is the Underlying Pathogenic Mechanism of Cherubism Noam Levaot, Oleksandr Voytyuk, Ioannis D. Dimitriou, Cell BiologyBiochemistryNatural SciencesTankyrase-mediated DestructionMolecular Biology	2011	188
In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target Xiaoqing Wang, Collin Tokheim, Shengqing Gu, Cell MedicineImmunologyTumor ImmunityVivo Crispr ScreensGene Editing	2021	182
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets Xintao Qiu, Nadia Boufaied, Tarek Hallal, Nature Communications	2022	139
TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response Zexian Zeng, Cheryl J. Wong, Lin Yang, Nucleic Acids Research	2021	123
Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells Gordon Chan, Laurene S. Cheung, Wentian Yang, Blood	2011	96
Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer Shuang Zhang, Sonia Iyer, Hao Ran, Cancer Discovery	2020	86

Page 1